Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 429


Comparison of analytical and clinical performances of the digene HC2 HPV DNA assay and the INNO-LiPA HPV genotyping assay for detecting high-risk HPV infection and cervical neoplasia among HIV-positive African women.

Ngou J, Gilham C, Omar T, Goumbri-Lompo O, Doutre S, Michelow P, Kelly H, Didelot MN, Chikandiwa A, Sawadogo B, Delany-Moretlwe S, Meda N, Costes V, Mayaud P, Segondy M.

J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):162-8. doi: 10.1097/QAI.0000000000000428.


Comparison of INNO-LiPA genotyping extra and hybrid capture 2 assays for detection of carcinogenic human papillomavirus genotypes.

Barzon L, Militello V, Pagni S, Palù G.

J Clin Virol. 2012 Nov;55(3):256-61. doi: 10.1016/j.jcv.2012.07.013. Epub 2012 Aug 9.


Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.

Dong L, Feng RM, Zhang L, Xu XQ, Zhao XL, Wang MZ, Qiao YL, Zhao FH.

J Gynecol Oncol. 2017 Sep;28(5):e66. doi: 10.3802/jgo.2017.28.e66. Epub 2017 Jun 5.


Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study.

Rao A, Sandri MT, Sideri M, Young S, Sharma A, Behrens C.

J Clin Virol. 2013 Sep;58(1):161-7. doi: 10.1016/j.jcv.2013.06.041. Epub 2013 Jul 27.


Performance of careHPV for detecting high-grade cervical intraepithelial neoplasia among women living with HIV-1 in Burkina Faso and South Africa: HARP study.

Segondy M, Kelly H, Magooa MP, Djigma F, Ngou J, Gilham C, Omar T, Goumbri-Lompo O, Michelow P, Doutre S, Clavero O, Chikandiwa A, Sawadogo B, Didelot MN, Costes V, Méda N, Delany-Moretlwe S, Mayaud P.

Br J Cancer. 2016 Aug 9;115(4):425-30. doi: 10.1038/bjc.2016.207. Epub 2016 Jul 19.


High performance of combined HPV testing and genotyping for HPV16/18/52/58 in triaging women with minor cervical cytological abnormalities in northern Thailand.

Khunamornpong S, Settakorn J, Sukpan K, Srisomboon J, Intaraphet S, Siriaunkgul S.

J Med Virol. 2016 Jan;88(1):135-43. doi: 10.1002/jmv.24290. Epub 2015 Jun 30.


Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.

Sandri MT, Lentati P, Benini E, Dell'Orto P, Zorzino L, Carozzi FM, Maisonneuve P, Passerini R, Salvatici M, Casadio C, Boveri S, Sideri M.

J Clin Microbiol. 2006 Jun;44(6):2141-6.


Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.

Verdoodt F, Szarewski A, Halfon P, Cuschieri K, Arbyn M.

Cancer Cytopathol. 2013 Dec;121(12):675-87. doi: 10.1002/cncy.21325. Epub 2013 Jul 23. Review.


Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA Genotyping assay to screen the discordant results.

Mo LZ, Monnier-Benoit S, Kantelip B, Petitjean A, Riethmuller D, Prétet JL, Mougin C.

J Clin Virol. 2008 Feb;41(2):104-10. Epub 2007 Nov 26.


Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.

Polman NJ, Oštrbenk A, Xu L, Snijders PJF, Meijer CJLM, Poljak M, Heideman DAM, Arbyn M.

J Clin Microbiol. 2017 Dec;55(12):3544-3551. doi: 10.1128/JCM.01282-17. Epub 2017 Oct 11.


Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study.

Gillio-Tos A, De Marco L, Carozzi FM, Del Mistro A, Girlando S, Burroni E, Frayle-Salamanca H, Giorgi Rossi P, Pierotti P, Ronco G; New Technologies for Cervical Cancer Screening Working Group.

J Clin Microbiol. 2013 Sep;51(9):2901-7. doi: 10.1128/JCM.01047-13. Epub 2013 Jun 26.


Comparison of Abbott RealTime High Risk HPV and Hybrid Capture 2 for the detection of high-risk HPV DNA in a referral population setting.

Venturoli S, Leo E, Nocera M, Barbieri D, Cricca M, Costa S, Santini D, Zerbini M.

J Clin Virol. 2012 Feb;53(2):121-4. doi: 10.1016/j.jcv.2011.10.016. Epub 2011 Nov 23.


Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples.

Jentschke M, Soergel P, Hillemanns P.

J Virol Methods. 2013 Oct;193(1):131-4. doi: 10.1016/j.jviromet.2013.05.009. Epub 2013 May 23.


Comparison of the AdvanSure HPV GenoBlot assay with the INNO-LiPA HPV genotyping assay for human papillomavirus genotyping.

Chung HS, Lee M.

J Clin Virol. 2014 May;60(1):34-8. doi: 10.1016/j.jcv.2014.01.027. Epub 2014 Feb 9.


Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test.

Pista A, Verdasca N, Oliveira A.

J Med Virol. 2011 Feb;83(2):272-6. doi: 10.1002/jmv.21952.


[Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].

Li RZ, Shi JF, Zhou QZ, Wu RF, Li N, Wu LN, Zhou YQ, Wang Q, Liu ZH, Liu B, Qiao YL.

Zhonghua Yi Xue Za Zhi. 2006 Feb 7;86(5):307-11. Chinese.


Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.

Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J.

Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Review. Erratum in: Vaccine. 2013 Dec 16;31(52):6266.


Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica.

Safaeian M, Herrero R, Hildesheim A, Quint W, Freer E, Van Doorn LJ, Porras C, Silva S, González P, Bratti MC, Rodriguez AC, Castle P; Costa Rican Vaccine Trial Group.

J Clin Microbiol. 2007 May;45(5):1447-54. Epub 2007 Mar 7.

Supplemental Content

Support Center